Global HER2 Inhibitors Market , By Treatment (Monotherapy, Combination Therapy), Application (Squamous Cell Carcinoma, Gastric Cancer, Adenocarcinoma, Breast Cancer, Large Cell Carcinoma, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Global HER2 Inhibitors Market
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Human epidermal growth factor receptor (HER2) inhibitors are tyrosine kinase inhibitors or monoclonal antibodies that slow down or stop the cell growth hence reducing the risk for cancer growth. Human epidermal growth factor receptors are the transmembrane receptors that have a transmembrane receptor, extracellular building component and intracellular tyrosine kinase component.
Rise in the prevalence of breast cancer and gastric cancer is the major factor that will accelerate the market growth. Furthermore, growing healthcare expenditure, increase in the investment for research activities, growing government funding and rising initiatives by government and private organisations to spread awareness about the cancer are the factors that will expand the HER2 inhibitors market.
Rise in the research and development activities and upsurge in the sale of approved HER2 inhibitors in the will provide beneficial opportunities for the HER2 inhibitors market in the forecast period of 2021-2028.
However, high cost of treatment, side effects of HER2 inhibitors, uncertainties in the introduction of herceptin biosimilars and presence of alternative treatment options are the factors that will act as market restraints and will further challenge the HER2 inhibitors market in the forecast period mentioned above.
This HER2 inhibitors market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the HER2 inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of treatment, the HER2 inhibitors market is segmented into monotherapy and combination therapy.
- On the basis of application, the HER2 inhibitors market is segmented into squamous cell carcinoma, gastric cancer, adenocarcinoma, breast cancer, large cell carcinoma and others.
- On the basis of end-users, the HER2 inhibitors market is segmented into clinic, hospital and others.
The HER2 inhibitors market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
HER2 Inhibitors Market Country Level Analysis
HER2 inhibitors market is analyzed and market size information is provided by the country, treatment, application, end-users and distribution channel as referenced above.
The countries covered in the HER2 inhibitors market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the HER2 inhibitors market due to the presence of major key players, high sale of approved HER2 inhibitors due to rising prevalence of breast cancer, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, increasing incidence of cancer, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
HER2 inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global HER2 Inhibitors Market Share Analysis
HER2 inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to HER2 inhibitors market research.
The major players covered in the HER2 inhibitors market report are Biocon, F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck Sharp & Dohme Corp., Novartis AG, Mylan N.V., Puma Biotechnology, Inc., Pfizer Inc., Boehringer Ingelheim International GmbH., Johnson & Johnson Private Limited, Genentech, Inc., GlaxoSmithKline plc, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-